{"name": "Aegerion Pharmaceuticals",
 "permalink": "aegerion-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/aegerion-pharmaceuticals",
 "homepage_url": "http://www.aegerion.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2005,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "908-707-2100",
 "description": "",
 "created_at": "Thu Sep 16 02:52:29 UTC 2010",
 "updated_at": "Fri May 31 04:35:08 UTC 2013",
 "overview": "\u003Cp\u003EAegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       69],
      "assets/images/resized/0010/1935/101935v1-max-150x150.png"],
     [[183,
       85],
      "assets/images/resized/0010/1935/101935v1-max-250x250.png"],
     [[183,
       85],
      "assets/images/resized/0010/1935/101935v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO \u0026 Director",
    "person":
     {"first_name": "Marc",
      "last_name": "Beer",
      "permalink": "marc-beer",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$1.5M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://online.wsj.com/article/BT-CO-20101011-710139.html",
    "source_description": "IPO Hopeful Aegerion Pharmaceuticals Returns To Investors For $1.5M",
    "raised_amount": 1500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 10,
    "funded_day": 11,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "1140 Route 22 East",
    "address2": "Suite 304 ",
    "zip_code": "08807 ",
    "city": "Bridgewater",
    "state_code": "NJ",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "has named Martha Carter as chief regulatory officer ",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 7,
    "source_url": "http://www.masshightech.com/stories/2011/02/07/daily13-Aegerion-names-regulatory-vet-Carter-to-CRO-post.html",
    "source_text": null,
    "source_description": "Aegerion names regulatory vet Carter to CRO post",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Aegerion Pharmaceuticals",
      "permalink": "aegerion-pharmaceuticals"}},
   {"description": "granted orphan drug designation from the U.S. Food and Drug Administration for its treatment of familial chylomicronemia (FC), a rare genetic disorder",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 16,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily46-Aegerion-gains-orphan-drug-status-for-lipid-disorder-drug.html",
    "source_text": null,
    "source_description": "Aegerion gains orphan drug status for lipid disorder drug",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Aegerion Pharmaceuticals",
      "permalink": "aegerion-pharmaceuticals"}},
   {"description": "received positive data from a Phase 3 trial of its potential treatment for a rare genetic type of extremely high cholesterol",
    "stoned_year": 2011,
    "stoned_month": 6,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/05/30/daily18-Aegerion-returns-positive-data-for-cholesterol-treatment.html",
    "source_text": null,
    "source_description": "Aegerion returns positive data for cholesterol treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Aegerion Pharmaceuticals",
      "permalink": "aegerion-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ: AEGR"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}